Authors:
Chen, C
Dagnino, R
Huang, CQ
McCarthy, JR
Grigoriadis, DE
Citation: C. Chen et al., 1-Alkyl-3-amino-5-aryl-1H-1,2,4]triazoles: Novel synthesis via cyclizationof N-acyl-S-methylisothioureas with alkylhydrazines and their potent corticotropin-releasing factor-1 (CRF1) receptor antagonist activities, BIOORG MED, 11(24), 2001, pp. 3165-3168
Authors:
Mackay, KB
Bozigian, H
Grigoriadis, DE
Loddick, SA
Verge, G
Foster, AC
Citation: Kb. Mackay et al., Neuroprotective effects of the CRF1 antagonist R121920 after permanent focal ischemia in the rat, J CEREBR B, 21(10), 2001, pp. 1208-1214
Authors:
Pelleymounter, MA
Joppa, M
Carmouche, M
Cullen, MJ
Brown, B
Murphy, B
Grigoriadis, DE
Ling, N
Foster, AC
Citation: Ma. Pelleymounter et al., Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF, J PHARM EXP, 293(3), 2000, pp. 799-806
Authors:
Maciejewski-Lenoir, D
Heinrichs, SC
Liu, XJ
Ling, N
Tucker, A
Xie, Q
Lappi, DA
Grigoriadis, DE
Citation: D. Maciejewski-lenoir et al., Selective impairment of corticotropin-releasing factor(1) (CRF1) receptor-mediated function using CRF coupled to saporin, ENDOCRINOL, 141(2), 2000, pp. 498-504
Citation: Eb. De Souza et De. Grigoriadis, Multiple brain corticotropin-releasing factor receptors and binding protein, HAND CHEM N, 16, 2000, pp. 477-508
Authors:
McCarthy, JR
Heinrichs, SC
Grigoriadis, DE
Citation: Jr. Mccarthy et al., Recent advances with the CRF1 receptor: Design of small molecule inhibitors, receptor subtypes and clinical indications, CUR PHARM D, 5(5), 1999, pp. 289-315